| 000 | 01550 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517025815.0 | ||
| 264 | 0 | _c20160108 | |
| 008 | 201601s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-015-1072-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKümler, Iben | |
| 245 | 0 | 0 |
_aA phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. _h[electronic resource] |
| 260 |
_bBMC cancer _cFeb 2015 |
||
| 300 |
_a78 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCamptothecin _xadministration & dosage |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xgenetics |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Dosage |
| 650 | 0 | 4 |
_aGenetic Markers _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIrinotecan |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xgenetics |
| 650 | 0 | 4 |
_aTopoisomerase I Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBalslev, Eva | |
| 700 | 1 | _aStenvang, Jan | |
| 700 | 1 | _aBrünner, Nils | |
| 700 | 1 | _aNielsen, Dorte | |
| 773 | 0 |
_tBMC cancer _gvol. 15 _gp. 78 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-015-1072-9 _zAvailable from publisher's website |
| 999 |
_c24816058 _d24816058 |
||